BENSALEM, Pa.--(BUSINESS WIRE)--
Law Offices of Howard G. Smith reminds investors that all purchasers of the securities of Geron Corporation (“Geron” or the “Company”) (GERN) between June 16, 2013 and March 11, 2014, inclusive (the “Class Period”), have until May 13, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Geron is a clinical stage biopharmaceutical company developing first-in-class therapies for cancer. The Company’s sole product candidate, imetelstat, is designed to inhibit cancer cell replication in hematologic myeloid malignancies such as myelofibrosis or acute myelogenous leukemia. The Complaint alleges that throughout the Class Period defendants misrepresented or failed to disclose that: (1) persistent low-grade liver function test (LFT) abnormalities had been observed in the Phase 2 study of imetelstat in essential thrombocythemia (ET) or polycythemia vera (PV) patients; (2) there was a potential risk of chronic liver injury following long-term exposure to imetelstat; and (3), as a result of the foregoing, defendants’ positive statements about the Company and the prospects for imetelstat lacked any reasonable basis and/or were materially false and misleading at all relevant times.
If you are a member of the Class described above, you have until May 13, 2014, to move the Court to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to email@example.com, or visit our website at http://www.howardsmithlaw.com.
- Company Legal & Law Matters
- Geron Corporation